Former Executive Vice President and Chief Financial Officer · Vir Biotechnology, Inc. (VIR)

Sung Lee

A named executive officer of Vir Biotechnology in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,739,557

Salary $184,527Stock awards $404,400Bonus $500,000

FY2023: $4,848,374

4th of 6 named executive officers at Vir Biotechnology by FY2024 total.

6 named officers on file for Vir Biotechnology, FY2024

Sung Lee’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • VIR’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vir Biotechnology’s whole pay program stands against its peers

  • Vir Biotechnology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VIR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed January 1, 1900 (DEF 14A).

Free

Get Sung Lee’s full pay file as a PDF — free

More than this page: up to 10 years of Sung’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Sung Lee compensation by year

Vir Biotechnology Summary Compensation Table · all 2 fiscal years held
In US dollars, as Vir Biotechnology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$402,865$184,527
Bonus$0$500,000
Stock awards$1,530,165$404,400
Option awards$2,472,231$616,640
Non-equity incentive$293,423$0
Pension and deferred compensation$0$0
All other$149,690$33,990
Total$4,848,374$1,739,557

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vir Biotechnology, Inc. DEF 14A filed January 1, 1900, accession 0001628280-25-018119, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vir Biotechnology, Inc. filed document, accession 0001628280-25-018119. Every figure is read from that document and cited to the page and table it appears in. Filed January 1, 1900.

$4.8M
$1.7M
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU66,500$668,990—
Option133,000—$23.01

Per the Outstanding Equity Awards at Fiscal Year-End table in Vir Biotechnology, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Vir Biotechnology’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Marianne De BackerChief Executive Officer and Director$9,255,903
Mark EisnerExecutive Vice President and Chief Medical Officer$2,756,265
Jason O'ByrneExecutive Vice President and Chief Financial Officer$1,919,827
Sung Lee · this pageFormer Executive Vice President and Chief Financial Officer$1,739,557
Vanina de VerneuilExecutive Vice President, General Counsel and Corporate Secretary$1,669,471
Ann HanlyExecutive Vice President and Chief Technology Officer$1,395,162

The full Vir Biotechnology compensation record

free company brief

This page is one person within Vir Biotechnology's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vir Biotechnology proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vir Biotechnology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Sung Lee's compensation dossier · One-time report. No refunds.